AJANTA PHARMA SHARE BUYBACK
Balancing Act: With greater capex comes lower dividend
The dividend payout ratio is the proportion of a company's earnings paid to shareholders as dividends. This payout tends to be lower in times when companies spend more on expansion. Companies with a high cash flow in mature industries tend to have higher dividend payout ratios.
Ahead of June 4, be relatively light & in cash; curtail trading: Dipan Mehta
Dipan Mehta advises caution and light trading ahead of the upcoming election dates. He emphasizes the importance of being in cash and watching the election results closely for investment decisions.
Ajanta Pharma buyback: Last day today to buy shares for Rs 285 crore special situation opportunity
Ajanta Pharma has set May 30 as the record date for its Rs 285 crore share buyback,. The buyback, at a premium of 12.6%, targets 10,28,881 equity shares, constituting 8.34% of the company's aggregate equity. Amidst strong financials, the company reported a 66% YoY growth in PAT and a 20% YoY increase in revenue in its Q4 results.
Be selective in FMCG stocks, in infrastructure, wait for dips: Gurmeet Chadha
Gurmeet Chadha says one of the main issues with most EPC construction names is the working capital cycle and margins because the projects are long gestation, you do not know what commodity prices would behave and people have some memories of 2003 to 2008 when there was euphoria and followed by a 10-year hiatus.
Ajanta Pharma’s Rs 285 crore share buyback can yield up to 6% return for retail investors
Ajanta Pharma has fixed May 30 as the record date for its buyback of 0.82% of the aggregate paid-up share capital of the company at Rs 2,770 per share. The pharma stock was trading at Rs 2,399.55, up 1% on BSE around 1:30 pm on Monday.
Technical Breakout Stocks: How to trade Ajanta Pharma, BHEL and Hindustan Zinc on Monday?
Indian market witnessed profit-taking on Friday tracking muted global cues. The S&P BSE Sensex plunged more than 700 points while the Nifty50 closed below 22,500 levels.
Ajanta Pharma shares jump over 13% on strong Q4 results, buyback plans
Ajanta Pharma shares jumped 13% to Rs 2,532 in Friday's trade on BSE after the firm's consolidated net profit increased 66% year-on-year (YoY) to Rs 203 crore in the March quarter, aided by robust sales across domestic and international markets. The drug maker had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal.
Ajanta Pharma Q4 Results: Net profit soars 66% YoY to Rs 203 cr
Revenue from operations rose to Rs 1,054 crore in the fourth quarter of FY24 as compared with Rs 882 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. For the year ended March 31, 2024, the company posted a consolidated net profit of Rs 816 crore as against Rs 588 crore in the 2022-23 fiscal year.
Ajanta Pharma announces Rs 285 crore share buyback at 24% premium
Ajanta Pharma on Thursday announced a Rs 285 crore buyback of up to 10.28 lakh shares through a tender offer at a price of Rs 2,770 — a premium of 24% --- against Thursday’s closing price of Rs 2,233.
Pharma, healthcare top bets of fund managers in March
They also purchased insurance stocks like SBI Life, HDFC Life, and ICICI Prudential Life Insurance after favourable guidelines on the surrender value of policies were announced by the insurance regulator IRDAI. Also, the recent removal of the age limit on availing of health insurance is seen as boosting the prospects of life insurance companies.
Multibagger Aurobindo Pharma, 4 other pharma stocks see solid mutual fund action in February
Mutual funds sold Sun Pharma shares worth Rs 2,300 crore. The pharma major was among the top 10 holdings of Aditya Birla Sun Life, ICICI Pru, Sundaram MF, and Nippon India with stakes of 2.16%, 3.29%, 1.56%, and 1.20%, respectively.
Old boys yet new kids: 4 largecap stocks which meet parameters for long-term investing
Given the trend of short correction and sharp recovery which the market and especially Nifty has seen in the last few months, it appears that nothing can go wrong with the stock price. But there are enough examples from the recent past and also the long history of markets that most wrong investment decisions are made in these times. if one is thinking about increasing the exposure it would be better to stay with large caps. This is not to say that one would not be wrong in buying large caps but as they would be able to weather any storm which might emerge due to any reason, the damage would be controlled. Even in the large cap category stay with stocks, which dont find place in headlines very often but on many parameters are better than well known names and in fact their performance in the last one year is indicative that even the street is in mood to recognize them.
Business and valuation tailwinds to help in outperformance? 5 Indian pharma stocks with upside potential of up to 32%
Just before the whole market was consumed by the PSU rally, one sector that came into the limelight after many years of underperformance was the Indian pharma companies, yes they are very different in every sense from MNC pharma. During the PSU rally, these pharma stocks have been consolidating, however, in the last few days, some of them have once again started reacting to positive developments in the individual company indicating that there is money on the sideline that is ready to come into these stocks. Sectors like pharma which have seen a very long phase of business remodelling and valuation readjustment need to be brought back on the watch list. It might be too early to call, but if a re-rating gets momentum once again then they might be better candidates for volatile markets.
Zydus Lifesciences Q3 Results: Firm beats profit estimates; approves shares buyback
Indian generic drugmaker Zydus Lifesciences reported a bigger-than-expected rise in third-quarter profit on Friday, driven by strong sales in its domestic and overseas markets.
Diwali doublers: InCred gunning for 3 stocks that can gain up to 311% in 3 years
A bottoms-up stock analysis of companies with strong business momentum, healthy ROE/ROCE profile, at least 15% EPS CAGR for FY24-26F, and a forward PE/PBV valuation near mean/ below mean of the last 5-10 years shows 10 stocks can rally within 46-311% in 3 years.
Breakout Stocks: How Ajanta Pharma, Titan Company and KEC International are looking on charts for Thursday’s trade
After Tuesday’s correction in the small and midcap space, many pharma stocks gave a good up move by forming a new all-time high on Wednesday. Ajanta Pharma gave an excellent breakout in daily and weekly timeframe but gave back gains in the second half
Breakout Stocks: How are Intellect Design, Ajanta Pharma and NCC looking on charts for Monday’s trade?
Sectorally, buying was seen in utilities, power, realty, and public sector stocks while selling was seen in IT, banks and oil & gas. Stocks that were in focus include names like Intellect Design Arena which rose by about 20%, Ajanta Pharma gained more than 4% and NCC closed with gains of over 7% to a fresh 52-week high on Friday.
Buy Ajanta Pharma, target price Rs 1580: ICICI Securities
Ajanta Pharma, incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 18277.05 Crore) operating in Pharmaceuticals sector.
Long-term investing: 5 midcaps with high ROE & consistent ROCE
Every sector has different operating conditions which have high correlation with returns companies in that particular industry are able to generate. Whether it is ROCE, ROE or net margins all is dependent on the underlying business. The bigger question is how sustainable that number is as that is what determines whether they are able to generate long term wealth or not.
Load More
